ORR
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
ORR
Jun 25, 2024, 16:01 |
Insight
Paolo Tarantino: Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in Journal of Clinical Oncology
Paolo Tarantino shared on X: . "Phase 1 trial of the HER2 topo1 ADC SHR-A1811…
May 27, 2024, 04:03 |
Opinion
Rahul Banerjee: My top 10 ASCO 24 multiple myeloma abstracts
Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, shared…
May 24, 2024, 13:24 |
Insight
Erman Akkus Summarizes 5-year Results of CheckMate 040
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: “Nivolumab plus ipilimumab…
May 23, 2024, 09:20 |
Blog
Yakup Ergün Summarizes Final Results of RIGHT Choice
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on X:…
May 18, 2024, 14:00 |
Blog
Paolo Tarantino: Very promising activity with a new CDK4i
Paolo Tarantino shared the following post by ESMO on X, adding the following: "Very promising…
May 9, 2024, 00:16 |
Insight
Update CheckMate 9ER summarized by Sergio Cifuentes
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, posted on X: “Update CheckMate 9ER - PFS:…
All:
6
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube